Clinical Trials and Research
Making Progress Every Single Day
Last year, more than 3,300 people participated in clinical trials at the Cancer Center, leading to new knowledge and breakthrough therapies. Our clinical trials offer access to tomorrow's therapies today.
The Center for Cancer Research serves as the scientific engine for discovery for the Mass General Cancer Center.
The Mass General Cancer Center is committed to understanding the mechanisms by which the immune system works to kill cancer.
The CORE program conducts innovative research and educational programs to improve the experience and outcomes of patients and caregivers across the continuum of cancer care.
Progress in Targeted Cancer Care
Eradicating cancer takes commitment and creativity. We have both. Commitment to explore novel combinations of therapies. Creativity to collaborate, apply learnings, and advance treatment options.
Henri and Belinda Termeer Center for Targeted Therapies
The Termeer Center offers a comprehensive translational research program to speed the discovery and delivery of new targeted therapies to patients with early and advanced stage cancers.
Progress in Immunotherapy
The Mass General Cancer is proud to be an authorized treatment center for FDA approved CAR T-cell therapies for adult patients with lymphoma and for adult patients with multiple myeloma. Where, before, patients were given little or no hope, now there is real and meaningful scientific progress. Today it's CAR-T therapy. Tomorrow? We think big so you can dream big.
Progress in Early Cancer Detection
Center for Innovation in Early Cancer Detection
The Center for Innovation in Early Cancer Detection seeks to pair cancer detection technologies with clinical resources – with the goal of improving early cancer detection and treatment.
Browse Cancer Center Research Labs
Browse Research Areas
Clinical Research: Cancer Outcomes Research Program (CORe) | Cellular Immunotherapy Program | Center for Cancer Immunology | Center for Innovation in Early Cancer Detection | Therapeutic Intralesional Program